Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness DOI Creative Commons

Leah D. Punshon,

Maria Rita Fabbrizi, Ben Phoenix

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2065 - 2065

Published: Dec. 13, 2024

Photon (X-ray) radiotherapy is the most common treatment used in cancer therapy. However, exposure of normal tissues and organs at risk to ionising radiation often results a significant incidence low-grade adverse side effects, whilst high-grade toxicities also occur concerningly high rates. As an alternative, boron neutron capture therapy (BNCT) aims create densely helium lithium ions directly within cells, thus sparing surrounding cells but leading significantly more effective tumour control than X-rays. Although very promising for patients with recurring highly invasive tumours, BNCT does not currently have widespread use worldwide, part due limited reliable sources clinical use. Another limitation devising strategies selective optimal accumulation cells. Boronophenylalanine (BPA) major compound which takes advantage amino acid transporter LAT1 that overexpressed number human cancers. Additionally, there lack in-depth knowledge regarding impact on cellular DNA, molecular mechanisms are responsive treatment, important developing therapeutic using BNCT, unclear. In this review, we highlight current radiobiology acquired from vitro vivo studies, particularly context DNA damage repair, present evidence established new boron-containing compounds aimed enhancing specificity effectiveness treatment.

Language: Английский

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies DOI Open Access
Andrea Monti Hughes, Naonori Hu

Cancers, Journal Year: 2023, Volume and Issue: 15(16), P. 4091 - 4091

Published: Aug. 14, 2023

Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the source will conceivably pave way for new more numerous trials, leading up to much-needed randomized trials. In this context, it would be interesting consider implementation compounds strategies that significantly optimize BNCT. With aim mind, we analyzed, review, those articles published between 2020 2023 reporting were proved therapeutically useful vitro and/or vivo radiobiological studies, critical step translation setting. We also explored pathologies could potentially treated with newly developed theranostic agents. All these advances intend solve limitations questions arise during patient treatment field, other therapies. sense, active communication clinicians, radiobiologists, all disciplines improve cancer patients, cost- time-effective way.

Language: Английский

Citations

38
Improved Boron Neutron Capture Therapy Using Integrin αvβ3-Targeted Long-Retention-Type Boron Carrier in a F98 Rat Glioma Model DOI Creative Commons
Kohei Tsujino, Hideki Kashiwagi, Kai Nishimura

et al.

Biology, Journal Year: 2023, Volume and Issue: 12(3), P. 377 - 377

Published: Feb. 27, 2023

Integrin αvβ3 is more highly expressed in high-grade glioma cells than normal tissues. In this study, a novel boron-10 carrier containing maleimide-functionalized closo-dodecaborate (MID), serum albumin as drug delivery system, and cyclic arginine-glycine-aspartate (cRGD) that can target integrin was developed. The efficacy of boron neutron capture therapy (BNCT) targeting the brain rats using cRGD-functionalized MID-albumin conjugate (cRGD-MID-AC) evaluated. F98 exposed to boronophenylalanine (BPA), cRGD-MID-AC, cRGD + MID were used for cellular uptake neutron-irradiation experiments. An glioma-bearing rat tumor model biodistribution experiments after BPA or cRGD-MID-AC administration. BNCT had sufficient cell-killing effect vitro, similar with BPA. experiments, accumulated tumor, highest concentration observed 8 h Significant differences between untreated group groups vivo through log-rank test. Long-term survivors only intravenous These findings suggest selective against gliomas mechanism different from

Language: Английский

Citations

14
Targeting the organelle for radiosensitization in cancer radiotherapy DOI Creative Commons

Xiaoyan Sun,

Lin-Jie Wu, Lina Du

et al.

Asian Journal of Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 19(2), P. 100903 - 100903

Published: March 11, 2024

Radiotherapy is a well-established cytotoxic therapy for local solid cancers, utilizing high-energy ionizing radiation to destroy cancer cells. However, this method has several limitations, including low energy deposition, severe damage surrounding normal cells, and high tumor resistance radiation. Among various radiotherapy methods, boron neutron capture (BNCT) emerged as principal approach improve the therapeutic ratio of malignancies reduce lethality tissue, but it remains deficient in terms insufficient accumulation well short retention time, which limits curative effect. Recently, series radiosensitizers that can selectively accumulate specific organelles cells have been developed precisely target radiotherapy, thereby reducing side effects tissue damage, overcoming radioresistance, improving radiosensitivity. In review, we mainly focus on field nanomedicine-based discuss organelle-targeted radiosensitizers, specifically nucleus, mitochondria, endoplasmic reticulum lysosomes. Furthermore, carriers used BNCT are particularly presented. Through demonstrating recent developments radiosensitization, hope provide insight into design clinical treatment.

Language: Английский

Citations

6
In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection DOI Open Access
Tainah Dorina Marforio, Andrea Carboni, Matteo Calvaresi

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(20), P. 4944 - 4944

Published: Oct. 11, 2023

Carboranes have emerged as one of the most promising boron agents in neutron capture therapy (BNCT). In this context, vivo studies are particularly relevant, since they provide qualitative and quantitative information about biodistribution these molecules, which is utmost importance to determine efficacy BNCT, defining their localization (bio)accumulation, well pharmacokinetics pharmacodynamics. First, we gathered a detailed list carboranes used for studies, considering synthesis carborane derivatives or use delivery system such liposomes, micelles nanoparticles. Then, formulation employed cancer model each were identified. Finally, examined analytical aspects concerning detection, identifying main methodologies applied literature ex analysis. The present work aims identify current strengths weakness establishing bottlenecks best strategies future applications.

Language: Английский

Citations

10
Translational research of boron neutron capture therapy for spinal cord gliomas using rat model DOI Creative Commons

Ryo Kayama,

Kohei Tsujino, Shinji Kawabata

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: April 9, 2024

Boron neutron capture therapy (BNCT) is a type of targeted particle radiation with potential applications at the cellular level. Spinal cord gliomas (SCGs) present substantial challenge owing to their poor prognosis and lack effective postoperative treatments. This study evaluated efficacy BNCT in rat SCGs model employing Basso, Beattie, Bresnahan (BBB) scale assess locomotor activity. We confirmed presence adequate vitro boron concentrations F98 glioma 9L gliosarcoma cells exposed boronophenylalanine (BPA) vivo tumor concentration 2.5 h after intravenous BPA administration. In irradiation significantly enhanced survival group when compared that untreated group, minimal BBB reduction all sham-operated groups. These findings highlight as promising treatment option for SCGs.

Language: Английский

Citations

2
Exploring boron neutron capture therapy as a promising treatment for spinal cord gliomas: in vivo efficacy in rat models DOI Creative Commons
Shinji Kawabata,

Ryo Kayama,

Kohei Tsujino

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 8, 2024

Abstract Boron neutron capture therapy (BNCT) is a type of targeted particle radiation with potential applications at the cellular level. Spinal cord gliomas (SCGs) present substantial challenge owing to their poor prognosis and lack effective postoperative treatments. This study evaluated efficacy BNCT in rat SCGs model employing Basso, Bresnahan, Beattie (BBB) scale assess locomotor activity. We confirmed presence adequate vitro boron concentrations F98 9L cells exposed boronophenylalanine (BPA) vivo tumor concentration 2.5 h after intravenous BPA administration. In irradiation significantly enhanced survival group when compared that untreatedgroup, minimal BBB reduction all sham-operated groups. These findings highlight BNCTas promising treatment option for SCGs.

Language: Английский

Citations

0
Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness DOI Creative Commons

Leah D. Punshon,

Maria Rita Fabbrizi, Ben Phoenix

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(24), P. 2065 - 2065

Published: Dec. 13, 2024

Photon (X-ray) radiotherapy is the most common treatment used in cancer therapy. However, exposure of normal tissues and organs at risk to ionising radiation often results a significant incidence low-grade adverse side effects, whilst high-grade toxicities also occur concerningly high rates. As an alternative, boron neutron capture therapy (BNCT) aims create densely helium lithium ions directly within cells, thus sparing surrounding cells but leading significantly more effective tumour control than X-rays. Although very promising for patients with recurring highly invasive tumours, BNCT does not currently have widespread use worldwide, part due limited reliable sources clinical use. Another limitation devising strategies selective optimal accumulation cells. Boronophenylalanine (BPA) major compound which takes advantage amino acid transporter LAT1 that overexpressed number human cancers. Additionally, there lack in-depth knowledge regarding impact on cellular DNA, molecular mechanisms are responsive treatment, important developing therapeutic using BNCT, unclear. In this review, we highlight current radiobiology acquired from vitro vivo studies, particularly context DNA damage repair, present evidence established new boron-containing compounds aimed enhancing specificity effectiveness treatment.

Language: Английский

Citations

0